Starsource Multitrade

Starsource Multitrade CROIC

Kontantafkast på investeret kapital (CROIC) for Starsource Multitrade (506365.BO) pr. 16. okt. 2026 er -823,60 %. I foregående år var Kontantafkast på investeret kapital (CROIC) -2,15 % — en ændring på 38.228,46 % (lavere).

CROIC

-823,60 %

YoY

38.228,46%

Senest opdateret:

Kontantafkast på investeret kapital (CROIC) for Starsource Multitrade er 2026 -823,60 % . Kontantafkast på investeret kapital (CROIC) for Starsource Multitrade var 2025 -2,15 % . Det falder dermed med 38.228,46% lavere sammenlignet med året før.

Starsource Multitrade CROIC historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

CROIC
Dato
CROIC
1. jan. 2019
-7,86 INR
1. jan. 2020
44,97 INR
1. jan. 2021
-3,71 INR
1. jan. 2022
-2,84 INR
1. jan. 2023
-5,89 INR
1. jan. 2024
5,65 INR
1. jan. 2025
-2,15 INR
1. jan. 2026
-823,60 INR
Starsource Multitrade CROIC historik
ÅRCROICYoY
-823,60 %+38.228,46%
-2,15 %-138,02%
5,65 %-195,95%
-5,89 %+107,16%
-2,84 %-23,43%
-3,71 %-108,26%
44,97 %-671,91%
-7,86 %-52,08%
-16,41 %-125,66%
63,96 %-212,32%
-56,94 %+5.610,72%
-1,00 %-70,79%
-3,41 %—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Starsource Multitrade Aktieanalyse

Hvad laver Starsource Multitrade? Starsource Multitrade Ltd, identified by the ticker symbol 506365.BO and ISIN INE320M01019, is a corporate entity registered in India with its headquarters located in Mumbai, Maharashtra. The company was originally established through an initial public offering on January 2, 1995. While the specific sector and industry classifications are currently listed as not applicable, the company's operational history and strategic direction are closely tied to its former identity as Chemo Pharma Laboratories Ltd. This previous incarnation operated within the pharmaceutical industry, focusing on the development and distribution of healthcare products. However, the corporate landscape has shifted significantly, and the entity is no longer engaged in its original pharmaceutical activities. According to available information, the firm currently has no active operations within its traditional business lines. Instead, the organization is in a transitional phase, actively exploring new business opportunities to redefine its market presence. The strategic intent of the current management is to pivot away from pharmaceuticals and acquire businesses in the power and chemicals sectors. This move represents a substantial change in the company's core focus, aiming to diversify its portfolio and enter entirely different industrial segments. The company's official website, https://www.thechemopharmalaboratoriesltd.com/, reflects its historical branding, although the operational reality has evolved. Investors and stakeholders monitoring the company should note that the absence of current operations means that recent financial performance may not reflect traditional revenue streams associated with pharmaceutical manufacturing or sales. The focus is currently on strategic acquisitions and business development rather than organic growth from existing products. The transition from a pharmaceutical manufacturer to a holding or investment vehicle targeting power and chemical assets suggests a long-term restructuring plan. Until new acquisitions are finalized and integrated, the company remains in a state of exploration and preparation. The headquarters in Mumbai serves as the administrative center for these strategic discussions and future operational planning. The lack of a defined sector classification further underscores the company's current status as an entity in flux, waiting for new business units to be acquired and operationalized. This profile highlights the significant shift from its historical roots in healthcare to its current ambitions in energy and industrial chemicals, marking a distinct chapter in the company's corporate evolution. Starsource Multitrade er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Starsource Multitrade aktie

Kontantafkast på investeret kapital (CROIC) for Starsource Multitrade er -823,60 % i 2026.

Kontantafkast på investeret kapital (CROIC) for Starsource Multitrade ændrede sig fra -2,15 % til -823,60 %, hvilket repræsenterer en ændring på 38.228,46 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Kontantafkast på investeret kapital (CROIC) Starsource Multitrade siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

CROIC måler det kontantafkast, der genereres på investeret kapital. I modsætning til ROIC bruger det frit pengeflow i stedet for bogførte gevinster og giver et renere rentabilitetsmål.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Kontantafkast på investeret kapital (CROIC)s Starsource Multitrade med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere Kontantafkast på investeret kapital (CROIC)s er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Kontantafkast på investeret kapital (CROIC).

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Rentabilitet — Starsource Multitrade

Alle nøgletal — Starsource Multitrade